JP2009530415A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530415A5
JP2009530415A5 JP2009501678A JP2009501678A JP2009530415A5 JP 2009530415 A5 JP2009530415 A5 JP 2009530415A5 JP 2009501678 A JP2009501678 A JP 2009501678A JP 2009501678 A JP2009501678 A JP 2009501678A JP 2009530415 A5 JP2009530415 A5 JP 2009530415A5
Authority
JP
Japan
Prior art keywords
solid dispersion
pharmaceutical composition
polymer
surfactant
multiple polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009501678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/064293 external-priority patent/WO2007109604A2/en
Publication of JP2009530415A publication Critical patent/JP2009530415A/ja
Publication of JP2009530415A5 publication Critical patent/JP2009530415A5/ja
Pending legal-status Critical Current

Links

JP2009501678A 2006-03-20 2007-03-19 医薬組成物 Pending JP2009530415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78442806P 2006-03-20 2006-03-20
PCT/US2007/064293 WO2007109604A2 (en) 2006-03-20 2007-03-19 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2009530415A JP2009530415A (ja) 2009-08-27
JP2009530415A5 true JP2009530415A5 (enExample) 2011-04-28

Family

ID=38523221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009501678A Pending JP2009530415A (ja) 2006-03-20 2007-03-19 医薬組成物

Country Status (11)

Country Link
US (4) US20070218138A1 (enExample)
EP (1) EP2001498A4 (enExample)
JP (1) JP2009530415A (enExample)
CN (1) CN101494979A (enExample)
AR (1) AR059978A1 (enExample)
AU (1) AU2007226983A1 (enExample)
CA (1) CA2645566A1 (enExample)
PE (2) PE20110286A1 (enExample)
TW (1) TW200812611A (enExample)
UY (1) UY30226A1 (enExample)
WO (1) WO2007109604A2 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PL2395004T3 (pl) * 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US20070225297A1 (en) 2006-03-16 2007-09-27 Perni Robert B Deuterated hepatitis C protease inhibitors
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
NZ596889A (en) 2006-04-07 2013-06-28 Vertex Pharma Use of amide indole derivatives as modulators of ATP-binding cassette transporters
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2009009182A (es) 2007-02-27 2009-09-04 Vertex Pharma Co-cristales y composiciones farmaceuticas que los comprenden.
EP2134717A2 (en) 2007-02-27 2009-12-23 Vertex Pharmceuticals Incorporated Inhibitors of serine proteases
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
NZ583699A (en) 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
WO2009114601A2 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
BRPI0909187A2 (pt) 2008-03-20 2015-08-04 Virun Inc Emulsões incluindo tocoferol de derivados de peg
BRPI0909185A2 (pt) * 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
EP2293796A1 (en) * 2008-06-10 2011-03-16 Janssen Pharmaceutica, N.V. Telaprevir dosing regimen
GB0815852D0 (en) * 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
CA2737481A1 (en) * 2008-09-16 2010-03-25 Douglas Ludtke Stable solid oral dosage co-formulations
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
TW201130502A (en) 2010-01-29 2011-09-16 Vertex Pharma Therapies for treating hepatitis C virus infection
KR101622441B1 (ko) 2010-03-23 2016-05-18 버런, 아이엔씨. 자당 지방산 에스테르를 포함하는 나노에멀전
SMT202100051T1 (it) * 2010-03-25 2021-03-15 Vertex Pharma Dispersione solida di una forma amorfa di (r)-1-(2,2-difluorobenzo[d][1,3]diossol-5-il)-n-(1-(2,3-diidrossipropil)-6-fluoro-2-(1-idrossi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropan-carbossamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
JPWO2011152297A1 (ja) * 2010-05-31 2013-08-01 アステラス製薬株式会社 トリアゾール化合物の固体分散体
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
WO2012009503A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
US20140308242A1 (en) 2010-10-21 2014-10-16 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
TWI558400B (zh) 2011-03-18 2016-11-21 艾伯維有限公司 苯基尿嘧啶化合物之調配物
WO2013006761A2 (en) * 2011-07-07 2013-01-10 Arqule, Inc. Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
EP2811847B1 (en) 2012-02-10 2017-12-13 Virun, Inc. Beverage compositions containing non-polar compounds
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
US20160039871A1 (en) * 2012-12-21 2016-02-11 Sandoz Ag Novel forms of telaprevir
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9732076B2 (en) 2013-03-15 2017-08-15 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
KR102639753B1 (ko) * 2013-12-31 2024-02-22 아센디아 파마슈티컬스, 엘엘씨 난수용성 화합물용 약제학적 조성물
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
JP2017523206A (ja) * 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN106620711B (zh) * 2015-11-03 2019-06-25 中国科学院大连化学物理研究所 一种含有白藜芦醇的组合物及其制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3022878C (en) * 2016-05-09 2024-04-30 Dispersol Technologies, Llc Improved drug formulations
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN118834201A (zh) 2016-12-01 2024-10-25 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
CN113490492B (zh) * 2019-03-04 2024-09-27 日本烟草产业株式会社 吡唑酰胺化合物的非晶质固体分散体
IL290789B2 (en) * 2019-08-26 2025-09-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR20230069144A (ko) 2020-09-14 2023-05-18 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
AR038375A1 (es) * 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
JP2007509950A (ja) * 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
WO2005043118A2 (en) * 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
RU2373923C2 (ru) * 2004-06-08 2009-11-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции

Similar Documents

Publication Publication Date Title
JP2009530415A5 (enExample)
JP2008501802A5 (enExample)
EP3417861B1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
JP2009502969A5 (enExample)
TWI666020B (zh) 固體分散製劑
RU2006147247A (ru) Фармацевтические композиции
JP2014523445A5 (enExample)
JP2009530415A (ja) 医薬組成物
WO2016038532A1 (en) Amorphous treprostinil diethanolamine
WO2016051368A1 (en) Complex of amorphous empagliflozin and a cyclodextrin
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
AU2015373104B2 (en) Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
WO2014102628A1 (en) Stable pharmaceutical composition comprising azilsartan medoxomil
US20180228826A1 (en) Fixed-dose combinations of antiviral compounds
CN110958880B (zh) 固体分散制剂
JP2010536837A5 (enExample)
JP2019516765A5 (enExample)
CN105939715A (zh) 抗病毒化合物的固定剂量组合
JP5297194B2 (ja) 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
CN111297822A (zh) 一种利伐沙班微丸胶囊及其制备方法
JP2024040951A5 (enExample)
KR20190038881A (ko) 무정형 소포스부비르를 포함하는 고체 제약 조성물
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
JP2016538312A (ja) 非晶質のコビシスタットの固体分散体
WO2017130219A1 (en) Amorphous solid dispersion of palbociclib